Rapport Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RAPP Nasdaq 2836 www.rapportrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rapport Therapeutics, Inc.

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - Jun 2nd, 2025 12:45 pm
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference - May 27th, 2025 5:00 am
Rapport Therapeutics to Host 2025 Investor and Analyst Day - May 21st, 2025 5:00 am
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth - May 16th, 2025 7:08 am
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update - May 8th, 2025 5:00 am
Rapport Therapeutics to Participate in Upcoming Investor Conferences - Apr 22nd, 2025 5:00 am
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - Mar 21st, 2025 5:00 am
Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock - Mar 15th, 2025 6:31 am
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares - Mar 15th, 2025 6:17 am
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 11th, 2025 5:00 am
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - Mar 3rd, 2025 5:00 am
Rapport Therapeutics announces new Phase 1 data for RAP-219 - Jan 10th, 2025 5:20 am
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - Jan 9th, 2025 7:12 am
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - Jan 9th, 2025 5:00 am
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn - Dec 7th, 2024 5:18 am
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures - Dec 6th, 2024 10:01 am
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting - Nov 14th, 2024 5:00 am
Rapport Therapeutics expects cash to fund requirements through 2026 - Nov 8th, 2024 5:18 am
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update - Nov 7th, 2024 5:00 am
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November - Nov 4th, 2024 5:00 am